The science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
From gene therapy to Long Covid, better assays are helping researchers move promising drug candidates from early studies into clinical trials. Dr Alexandre Lucas explains the technologies, challenges and innovations driving this progress.
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
Researchers at the University of Birmingham have developed a single-cell technique to track boron inside live tumour cells – making Boron Neutron Capture Therapy more effective in treating head and neck cancers.
Researchers have developed the first high-throughput tool to rapidly profile RNA modifications – a breakthrough that could lead to more precise treatments for cancer and antibiotic-resistant infections.
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
What if familiar lab formats could be redesigned to remove the weak points in permeability and absorbance testing? This article explores how design choices in common consumables can improve both speed and reproducibility in early-stage research.
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.